Medtronic, a medical device company, has announced the U.S. Food and Drug Administration (FDA) clearance for its MiniMed Connect that provide a mobile connection to critical information for managing diabetes.
According to the company, it is the first product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitor data on a smartphone and provides remote monitoring and text message notifications for their loved ones.
It also gives healthcare teams more suitable access to more comprehensive patient data so they can adjust their patients' care plans.
MiniMed Connect consists of a small device that easily fits on a keychain or in a pocket, a smartphone app for the person with diabetes, and a web display on desktop or mobile devices for their care partners.
The device securely transmits pump and sensor glucose data from the patient's MiniMed insulin pump to the app and web display, which shows real-time sensor glucose and insulin information on the phone.
The system also delivers preset text notifications to loved ones when the person with diabetes' glucose values go too high or too low, or when an alarm on the pump isn't cleared, providing greater peace of mind for care partners.
In addition, MiniMed Connect provides healthcare teams with more comprehensive data, and with more convenient access to their patients' diabetes data so they can adjust care plans.
"Engagement from people with diabetes, loved ones and healthcare providers is key to living well with diabetes. With MiniMed Connect, the entire care team can have access to critical diabetes data to inform the decisions that help people have better outcomes," said Annette Brüls, vice president and general manager, Diabetes Services and Solutions at Medtronic.